Mitchell Group Has Lowered By $1.45 Million Its Schlumberger LTD (SLB) Stake; Altimmune (ALT) Shorts Down By 1.32%

January 17, 2018 - By Adrian Erickson

Altimmune Incorporated (NASDAQ:ALT) had a decrease of 1.32% in short interest. ALT’s SI was 591,400 shares in January as released by FINRA. Its down 1.32% from 599,300 shares previously. With 102,300 avg volume, 6 days are for Altimmune Incorporated (NASDAQ:ALT)’s short sellers to cover ALT’s short positions. The stock decreased 1.05% or $0.02 during the last trading session, reaching $1.88. About 41,016 shares traded. Altimmune, Inc. (NASDAQ:ALT) has 0.00% since January 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Mitchell Group Inc decreased Schlumberger Ltd (SLB) stake by 7.95% reported in 2017Q3 SEC filing. Mitchell Group Inc sold 21,060 shares as Schlumberger Ltd (SLB)’s stock declined 11.04%. The Mitchell Group Inc holds 243,683 shares with $17.00M value, down from 264,743 last quarter. Schlumberger Ltd now has $107.34B valuation. The stock increased 0.41% or $0.32 during the last trading session, reaching $77.49. About 3.47 million shares traded. Schlumberger Limited (NYSE:SLB) has declined 3.30% since January 17, 2017 and is downtrending. It has underperformed by 20.00% the S&P500.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $29.38 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Since October 24, 2017, it had 0 insider buys, and 1 insider sale for $219,205 activity. 3,500 Schlumberger Limited (NYSE:SLB) shares with value of $219,205 were sold by SANDVOLD TORE I.

Investors sentiment is 0.88 in 2017 Q3. Its the same as in 2017Q2. It is flat, as 69 investors sold SLB shares while 596 reduced holdings. only 105 funds opened positions while 481 raised stakes. 1.20 billion shares or 11.55% more from 1.07 billion shares in 2017Q2 were reported. Thompson Rubinstein Inv Incorporated Or stated it has 2.24% of its portfolio in Schlumberger Limited (NYSE:SLB). Amarillo Fincl Bank invested 0.34% of its portfolio in Schlumberger Limited (NYSE:SLB). 11,073 are owned by Duncker Streett Commerce. 113,878 are held by Jacobs & Ca. 1St Source National Bank owns 53,401 shares. Kingfisher Limited Liability accumulated 18,847 shares. Heritage Wealth Advsr owns 17,533 shares. Nelson Van Denburg And Campbell Wealth Management Group Incorporated Limited Liability Corporation has 13,341 shares. Winch Advisory Service Limited Liability Company has invested 0.17% of its portfolio in Schlumberger Limited (NYSE:SLB). Livforsakringsbolaget Skandia Omsesidigt reported 0.17% stake. Chesley Taft Associate Limited invested in 49,840 shares. Moreover, Norinchukin Bank The has 0.24% invested in Schlumberger Limited (NYSE:SLB) for 174,597 shares. Wealthtrust Fairport Lc reported 58,887 shares or 0.43% of all its holdings. Systematic Fin LP owns 8,300 shares or 0.01% of their US portfolio. Kbc Grp Inc Nv holds 406,671 shares.

Among 35 analysts covering Schlumberger Limited. (NYSE:SLB), 27 have Buy rating, 1 Sell and 7 Hold. Therefore 77% are positive. Schlumberger Limited. had 128 analyst reports since July 22, 2015 according to SRatingsIntel. On Monday, October 19 the stock rating was maintained by Oppenheimer with “Outperform”. The stock has “Buy” rating by Citigroup on Wednesday, March 23. The company was maintained on Thursday, January 11 by Cowen & Co. Morgan Stanley maintained the shares of SLB in report on Monday, October 23 with “Overweight” rating. The firm earned “Buy” rating on Friday, April 7 by Jefferies. The stock has “Buy” rating by RBC Capital Markets on Friday, October 13. RBC Capital Markets maintained the shares of SLB in report on Thursday, July 20 with “Buy” rating. The firm earned “Overweight” rating on Tuesday, April 19 by Morgan Stanley. Suntrust Robinson initiated the shares of SLB in report on Wednesday, January 18 with “Hold” rating. The firm has “Outperform” rating by Cowen & Co given on Monday, April 25.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: